Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Sosei Group Corporation
Sosei Group Corporation
Activities:
Ingredients
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Metrion and Sosei Heptares to explore structure-based drug design
Sosei Heptares will have exclusive global rights to all molecules identified
Research & Development
Sosei Heptares and PharmEnable enter drug discovery collaboration
The companies will jointly conduct and share the costs of the discovery and development program and will co-own any resulting products
Research & Development
Sosei Heptares announces €40 million Medicxi investment
Two asset-centric companies have been formed to develop Sosei’s novel therapies for neurological diseases funded by Medicxi
Recruitment
Sosei appoints Interim CFO
Media
Changes in executive management at Sosei
Manufacturing
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Finance
Heptares Therapeutics enters agreement with Daichi Sankyo
The collaboration aims to discover and develop novel, small-molecules for the treatment of pain
Subscribe now